Latest Breaking News On - Acceleron pharma inc - Page 9 : comparemela.com

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M D , to Chief Medical Officer and Scott Coleman, Ph D , to Chief Development Officer - Xilio Therapeutics (NASDAQ:XLO)

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living

Julissa vianaMelissa forstMartin huberKatarina luptakovaScott colemanXilio therapeutics incCubist pharmaceuticalsCorporate communicationsLinkedin xilio therapeutics incMillennium pharmaceuticalsExchange commissionTesaro incBeth israel deaconess medical centerAcceleron pharma incConstellation pharmaceuticals incConstellation pharmaceuticals

FDA grants expanded approval for Bristol Myers Squibb anemia therapy

FDA grants expanded approval for Bristol Myers Squibb anemia therapy
njbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from njbiz.com Daily Mail and Mail on Sunday newspapers.

United statesTracey iracaGuillermo garcia maneroAcceleron pharma incBristol myers squibbDrug administrationUniversity of texas md anderson cancer centerMyelodysplastic syndromesCancer centerCell therapyAcceleron pharma

U S FDA Approves Bristol Myers Squibb s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | National Business

PRINCETON, N.J. (BUSINESS WIRE) Aug 28, 2023

United statesTracey iracaGuillermo garcia maneroBristol myers squibbUniversity of texas md anderson cancer centerExchange commissionAmerican society of clinical oncologyAcceleron pharma incEuropean hematology associationDrug administrationMyers squibbMyelodysplastic syndromesWendy short bartieCell therapyBristol myersAmerican society

U S FDA Approves Bristol Myers Squibb s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | Business

PRINCETON, N.J. (BUSINESS WIRE) Aug 28, 2023

United statesGuillermo garcia maneroBristol myers squibbTracey iracaUniversity of texas md anderson cancer centerAmerican society of clinical oncologyDrug administrationExchange commissionAcceleron pharma incEuropean hematology associationMyers squibbMyelodysplastic syndromesWendy short bartieCell therapyBristol myersAmerican society

Bristol-Myers Squibb (BMY) Announces FDA Approval of Reblozyl for Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

Bristol-Myers Squibb (BMY) Announces FDA Approval of Reblozyl for Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGuillermo garcia maneroTracey iracaBristol myers squibbDrug administrationUniversity of texas md anderson cancer centerAcceleron pharma incEuropean hematology associationAmerican society of clinical oncologyMyelodysplastic syndromesWendy short bartieCell therapyBristol myersAmerican societyClinical oncologyAnnual meeting